Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:47:52.012Z.
Calculation as of: 2026-10-06T18:47:52.012Z.
Quote observation: 2026-10-06T18:45:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 033b533528001a3499036996a5838431eca9b2abd512acbebbb4929ff412c5bb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$789.07M
EV/EBIT Ratio
N/A
TTM Avg
957.13x
3Y Avg
957.13x
5Y Avg
957.13x
Market Cap
$778.24M
EV/EBIT Ratio
14.58x
TTM Avg
14.71x
3Y Avg
18.13x
5Y Avg
17.67x
Market Cap
$774.41M
EV/EBIT Ratio
N/A
TTM Avg
15.22x
3Y Avg
6.50x
5Y Avg
6.50x
Market Cap
$800.49M
EV/EBIT Ratio
N/A
TTM Avg
103.45x
3Y Avg
72.64x
5Y Avg
72.64x
Market Cap
$760.53M
EV/EBIT Ratio
36.98x
TTM Avg
38.85x
3Y Avg
65.92x
5Y Avg
138.61x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | $781.97M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $789.07M | N/A | 957.13x | 957.13x | 957.13x |
| Varex Imaging Corporation (VREX)vs › | $778.24M | 14.58x | 14.71x | 18.13x | 17.67x |
| AdaptHealth Corp. (AHCO)vs › | $786.84M | N/A | 13.71x | 14.97x | 19.98x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $774.41M | N/A | 15.22x | 6.50x | 6.50x |
| Attovia Therapeutics, Inc. (ATTO)vs › | $763.35M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $800.49M | N/A | 103.45x | 72.64x | 72.64x |
| InMode Ltd. (INMD)vs › | $803.29M | 5.95x | 7.17x | 8.31x | 13.83x |
| Mesa Laboratories, Inc. (MLAB)vs › | $760.53M | 36.98x | 38.85x | 65.92x | 138.61x |
| Apnimed, Inc. (APMD)vs › | $755.45M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute